Recurrent Giant Mucoepidermoid Carcinoma of the Parotid: A Case Report and Review of Literature

Mucoepidermoid carcinoma is the most common salivary gland malignancy and about one third occurs in the parotid gland. The peak incidence is commonly seen between the third and fifth decades of life. It routinely presents as a fixed, painless mass below the ear. However, its presentation as a giant mass is exceedingly rare. Here, we report a case of a recurrent giant exophytic mucoepidermoid carcinoma in a young male. He underwent Revision Total Parotidectomy with Modified Radical neck dissection with Sural nerve grafting and an Anterolateral thigh flap reconstruction followed by Adjuvant radiotherapy. The rarity of the clinical presentation and the management challenges faced in a young male are being discussed in this case report.

Mammary Analogue Secretory Carcinoma of Submandibular Gland: A Case Report with Review of the Literature

Secretory carcinoma (SC) is a rare salivary gland tumor and has been recently included in the fourth edition of the World Health Organization classification of head and neck tumors. To understand the histopathologic findings and clinical behavior of mammary analogue secretory carcinoma (MASC) of the submandibular gland in a 23 year old female. MASC is an intriguing and rare malignant salivary gland tumor first described in 2010. It shares histologic, immunohistochemical and genetic features with secretory carcinoma of the breast. The clinical behavior of MASC ranges from slowly growing tumors to aggressive tumors that can cause widespread metastasis. Many cases of MASC were discovered in archived cases previously classified as pleomorphic adenoma, acinic cell carcinoma, mucoepidermoid carcinoma, and adenocarcinoma. They are only a few reported in submandibular gland. MASC is a newly recognized variant of salivary gland malignancy. Further research is needed to better delineate its overall prevalence and to define an appropriate treatment algorithm for this new clinical entity.

Expression of Mucins in Different Entities of Salivary Gland Cancer: Highest Expression of Mucin-1 in Salivary Duct Carcinoma : Mucin-1 - highest expression in Salivary Duct Carcinoma

Therapeutic options for advanced salivary gland cancer (SGC) are rare. Therefore, it was the aim of this study to investigate the extent and intensity of Mucin-1 (MUC1), Mucin-16 (MUC16), and Mucin-5AC (MUC5AC) as potential molecular targets using immunohistochemistry. The medical records of all patients who underwent primary surgery for salivary gland cancer with curative intent in a tertiary referral center between 1990 and 2018 were reviewed. Immunohistochemical staining for MUC1, MUC16, and MUC5AC was performed for all patients with sufficient formalin-fixed paraffin-embedded material, and a semi-quantitative combined score derived from the H-score for the cytoplasmatic, the membranous and the apical membrane was built for the most common entities of SGC. 107 patients with malignancies of the parotid (89.7%) and the submandibular gland (10.3%) were included. The most common entities were mucoepidermoid carcinoma (MuEp; n = 23), adenoid cystic carcinoma (AdCy; n = 22), and salivary duct carcinoma (SaDu; n = 21). The highest mean MUC1 combined score was found in SaDu with 223.6 (±91.7). The highest mean MUC16 combined score was found in MuEp with 177.0 (±110.0). The mean MUC5AC score was low across all entities. A higher MUC1 combined score was significantly associated with male gender (p = 0.03), lymph node metastasis (p < 0.01), lymphovascular invasion (p = 0.045), and extracapsular extension (p = 0.03). SaDu patients with MUC16 expression showed a significantly worse 5-year progression-free survival than those without MUC16 expression (p = 0.02). This is the first study to give a comprehensive overview of the expression of MUC1, MUC16, and MUC5AC in SGC. Since advanced SGCs lack therapeutic options in many cases, these results warrant in vitro research on therapeutic targets against MUC1 in SaDu cell lines and xenograft models.

Extent and Indications for Elective and Therapeutic Neck Dissection for Salivary Carcinoma

Although salivary gland malignancies account for only a small percentage of all head and neck cancers, the incidence is increasing. Furthermore, there is a wide variety of histologic subtypes which must be taken into account in the context of their location. Each is associated with a different rate of regional metastasis and overall survival. This article examines the incidence of salivary gland malignancies and provides evidence for the indications for and extent of elective or therapeutic neck dissection based on location, pathologic type, and histopathologic characteristics.

Development of sentinel lymph node biopsy technique in patients with salivary gland cancer using the IDEAL framework

BACKGROUND

Salivary cancer is rare and comprises a variety of histological subtypes and clinical behaviors. There is no agreed method of estimating the risk of occult metastasis or managing the clinically N0 neck.Sentinel node biopsy (SNB) may offer a solution but previous studies have not produced a reliable imaging protocol. This study uses novel technology and trial methodology to develop a reliable SNB technique, with primary aim to identify peri-and intraglandular sentinel nodes.

METHODS

IDEAL framework was used to undertake SNB in clinically node negative salivary gland cancer. Patients with cT1-2 N0 salivary cancer were eligible. Lymphoscintigraphy was undertaken using Tc-99 m labelled nanocoll. Injection technique as well as adjunctive use of freehand SPECT (fhSPECT), near-infrared (NIR) fluorescence imaging, and navigation-guided surgery were used and optimisied during the study protocol.

RESULTS

10 patients were recruited. Initial protocol of peritumoural injection of Tc99 m nanocoll showed poor image resolution. Subsequent adjustment to single intratumoural injection allowed identification of intraglandular sentinel nodes. Fh/SPECT and NIR fluorescence imaging found intraglandular lymph nodes otherwise not recognizable to the naked eye. In two cases occult lymph node metastasis were identified.

CONCLUSION

This study has shown the IDEAL framework is vital in allowing iterative changes in surgical protocol in the light of experience. This study has produced a reliable method for detection of sentinel nodes, in particular the ability to identify intra- and periglandular nodes with diagnosis of occult metastatic deposits and no false negative results. Our protocol can be readily transferred in to larger scale studies.

Neck dissection for salivary gland malignancies

Salivary gland carcinomas are diverse, and their biological behavior and surgical management are also variable and somewhat controversial. Cervical lymph node status is an important prognostic variable for salivary gland malignancies. Neck dissection should be undertaken if there is clinical or radiographic evidence of associated nodal metastasis in the neck. However, indications for elective neck dissections in a clinically N0 neck remains a controversial topic. This article describes indications for elective neck dissection in salivary gland malignancies, provides a detailed review of the neck dissection technique, and discusses postoperative management of these patients.

Secondary Salivary Gland Malignancy in Thyroid Cancer: A United States Population Based Study

Background

There is an increased risk of second primary malignancies with thyroid cancer. However, the risk and characters of secondary salivary gland malignancy (sSGM) in patients with thyroid cancer have not been evaluated before.

Methods

We used the Surveillance Epidemiology and End Results (SEER) 18 registry to identify thyroid cancer patients from 1973 to 2014. We then calculated the risk of sSGM using standardized incidence ratio and excess risk. Separately, all cases of primary salivary gland malignancy (pSGM) diagnosed between 1973 - 2014 were extracted from the SEER 18 registry, and their characteristics compared with sSGM using independent samples t-test for continuous variables and Chi-square tests for categorical variables.

Results

There were a total of 68,339 cases of primary thyroid cancer. Of these, 18 patients developed sSGM with the observed to expected ratio being 3.58 (95% CI: 2.12 to 5.65; P < 0.05) and excess risk being 0.48 per 10,000 population. The incidence of sSGM remained higher between 6 months to 10 years from the time of diagnosis of thyroid carcinoma. The risk of developing sSGM was significantly higher if they were below 60 years of age (O/E: 4.51; 95% CI: 2.33 - 7.88; P < 0.05), were females (O/E: 4.91; 95% CI: 2.80 - 7.97; P < 0.05), were whites (O/E: 3.04; 95% CI: 1.62 - 5.1 9; P < 0.05), had well-differentiated thyroid carcinoma (O/E: 9.70; 95% CI: 3.90 - 19.98; P < 0.05) or were treated with radioactive iodine (O/E: 5.26; 95% CI: 2.72 - 9.19; P < 0.05). While the proportion of females developing sSGM was significantly greater than those developing pSGM (88.9% vs. 44%; P < 0.05), there was no statistical difference between pSGM and sSGM in terms of the age at diagnosis, the proportion of patients diagnosed before 60 years of age, anatomic site of origin or the histological grade of tumor.

Conclusions

Patients with thyroid cancers are at an increased risk of developing sSGM than the general population. This risk is greater if the person is below 60 years of age, female, white, with well-differentiated thyroid carcinoma or is treated with radioactive iodine.

A Case Report of Rare Carcinoma Ex Pleomorphic Adenoma of Submandibular Gland and its Detailed Description

A 65-year-old female patient reported with a chief complaint of swelling in the left lower region of the jaw since two years. On clinical examination, the swelling was present on the mandibular left posterior region and measuring approximately 6.2 cm antero-posteriorly × 6.2 cm mediolaterally × 8.7 cm superioinferiorly. Initially, it was non tender but eventually it became tender. Fine needle aspiration was done to rule out any salivary gland pathology and report obtained was carcinoma ex pleomorphic adenoma. Then, excisional biopsy was taken and tissue sent for histopathology. Histopathological diagnosis was benign adenoma with carcinoma. Later serial sections of tissue were studied and came to the conclusion of carcinoma ex pleomorphic adenoma which was non invasive type and showed bizarre cells with neoplastic changes. Benign part was composed of myxomatous area with partial capsule. Neoplastic cells showed invasion into capsule and few necrotic areas were also present. Overall interpretation was favoured Non invasive carcinoma ex pleomorphic adenoma. So here, we reported a case of Carcinoma ex Pleomorphic Adenoma (CAEXPA) which is a deadly and rare variant of salivary gland malignancy.

Socioeconomic disparities and comorbidities, not race, affect salivary gland malignancy survival outcomes

OBJECTIVES/HYPOTHESIS

This study sought to determine whether comorbidities, race, and socioeconomic factors affect 5- and 10-year survival outcomes for patients with salivary gland malignancies treated at a single large academic institution with a large African American population.

STUDY DESIGN

A retrospective cohort study was performed of all patients with salivary gland malignancies, from 1990 to 2015, at a large academic medical center.

METHODS

Standard statistical analysis was performed using Kaplan-Meier survival curve analysis and Cox proportional hazard models.

RESULTS

The overall 5- and 10-year survival rates decreased with age ≥ 60 years (P < .001), stage 3 or 4 (P < .001), clinical T stage 3 or 4 (P < .001), and clinical N stage 1, 2, or 3 (P < .001). Living in a ZIP code with an increasing proportion of residents with a high school degree or less (P < .05), being male (P < .05), increasing age at the time of diagnosis (P < .001), and increasing Charlson comorbidity index (P < .05) detrimentally impacted survival at 5 and 10 years. Race was associated with socioeconomic variables, but race was not a prognostic indicator of survival.

CONCLUSIONS

Socioeconomic factors and comorbidities, not race, were negative prognostic indicators of survival of patients with salivary gland malignancies. Using race as a marker for socioeconomic status should be used with caution.

LEVEL OF EVIDENCE

4. Laryngoscope, 127:2545-2550, 2017.

Systemic therapy for recurrent or metastatic salivary gland malignancies

Salivary gland carcinomas are notoriously resistant to therapy and no standard of care exists. Due to the rarity of these malignancies, various histologies, and wide ranging clinical behavior it has been difficult to standardize systemic therapy. We have reviewed clinical prospective studies in the last 15 years with salivary gland malignancies involving cytotoxic chemotherapy and biologic agents including targeted therapies such as anti-HER-2, anti-EGFR therapies, and therapies directed at c-kit. Although the results of most trials are modest at best, there has been an increase in studies for salivary cancer in recent years and there are several promising treatment approaches in evolution. Every effort should be made to treat salivary gland malignancies under a clinical protocol and/or at a large multidisciplinary practice with clinicians experienced in treating these malignancies.

Salivary gland malignancies in children

With an annual incidence of less than 1 per million, salivary gland malignancies in children are rare, constituting less than 10% of pediatric head and neck cancer. Although over 20 histologic types of salivary gland cancer have been reported in adults, a smaller number have been observed in the pediatric population. Mucoepidermoid carcinoma is the most common histologic type, followed by acinic cell carcinoma. Since the majority of salivary gland carcinomas are diagnosed at an early stage, the overall prognosis is often favorable with complete surgical resection. To date, no prospective or retrospective data comparing outcomes of surgery alone versus multimodality therapy in the management of salivary gland malignancies in the pediatric population exists. Consequently, management decisions are made on a case-by-base basis, taking prognosis, treatment-related morbidity, and long-term sequelae into account.